Last reviewed · How we verify

Calmeran — Competitive Intelligence Brief

Calmeran (AZACYCLONOL) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: azacyclonol. Area: Other.

phase 2 azacyclonol Histamine H1 receptor, Sodium channel alpha subunits; brain (Types I, II, III) Other Small molecule Live · refreshed every 30 min

Target snapshot

Calmeran (AZACYCLONOL). Calmeran works by blocking the histamine H1 receptor, which helps to reduce allergic responses and other physiological effects caused by histamine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Calmeran TARGET AZACYCLONOL phase 2 azacyclonol Histamine H1 receptor, Sodium channel alpha subunits; brain (Types I, II, III)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (azacyclonol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Calmeran — Competitive Intelligence Brief. https://druglandscape.com/ci/azacyclonol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing